勘误：用镥177-前列腺特异性膜抗原对转移性去势抵抗性前列腺癌患者进行全身放疗时的反应评估：实体瘤反应评估标准、实体瘤正电子发射断层扫描反应标准、欧洲癌症研究与治疗组织以及通过镓68-前列腺特异性膜抗原正电子发射断层扫描-计算机断层扫描评估的MDA标准之间的比较。
Erratum: Evaluation of response in patients of metastatic castration resistant prostate cancer undergoing systemic radiotherapy with lutetium177-prostate-specific membrane antigen: A comparison between response evaluation criteria in solid tumors, positron-emission tomography response criteria in solid tumors, European organization for research and treatment of cancer, and MDA criteria assessed by gallium 68-prostate-specific membrane antigen positron-emission tomography-computed tomography.
出版信息
Urol Ann. 2020 Oct-Dec;12(4):396. doi: 10.4103/0974-7796.306735.
Abstract
[This corrects the article on p. 155 in vol. 11, PMID: 31040600.].
摘要
[这纠正了第11卷第155页上的文章，PMID: 31040600。]
相似文献
3
Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.前列腺特异性膜抗原标记的镓-68 正电子发射断层扫描/计算机断层扫描检测前列腺癌模型血管靶向光动力治疗后复发。
Eur Urol Focus. 2021 Mar;7(2):472-478. doi: 10.1016/j.euf.2019.06.008. Epub 2019 Jun 18.
4
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).ENZA-p 试验方案：一项随机二期临床试验，以前列腺特异性膜抗原作为治疗靶点和预后指标，评估恩扎卢胺（ANZUP 1901）治疗转移性去势抵抗性前列腺癌男性患者的疗效。
BJU Int. 2021 Nov;128(5):642-651. doi: 10.1111/bju.15491. Epub 2021 Jul 6.
5
Response assessment using [ Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer.使用[^18]F-Fluciclovine PSMA 配体 PET 对接受转移性去势抵抗性前列腺癌系统治疗的患者进行疗效评估。
[^18]F-Fluciclovine PSMA 配体 PET：氟[^18]F-氟代胆碱 PSMA 配体正电子发射断层扫描。
Prostate. 2020 Jan;80(1):74-82. doi: 10.1002/pros.23919. Epub 2019 Oct 15.
6
Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.转移性去势抵抗性前列腺癌患者全身治疗后前列腺特异性膜抗原PET反应评估与血清前列腺特异性抗原水平的一致性：一项系统评价和荟萃分析
Diagnostics (Basel). 2021 Apr 7;11(4):663. doi: 10.3390/diagnostics11040663.
7
Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.前列腺特异性膜抗原示踪剂在前列腺癌生化复发中的正电子发射断层扫描/计算机断层扫描检测率：系统评价和网络荟萃分析。
J Urol. 2021 Feb;205(2):356-369. doi: 10.1097/JU.0000000000001369. Epub 2020 Sep 16.
8
Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy.在根治性放疗后未达到生化复发的凤凰标准的患者中，使用前列腺特异性膜抗原正电子发射断层扫描检测复发性前列腺癌。
Eur Urol Oncol. 2021 Oct;4(5):821-825. doi: 10.1016/j.euo.2020.01.002. Epub 2020 Feb 20.
9
Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.镓 68 前列腺特异性膜抗原正电子发射断层扫描在晚期前列腺癌中的应用——更新的诊断效用、敏感性、特异性和前列腺特异性膜抗原阳性病变的分布：系统评价和荟萃分析。
Eur Urol. 2020 Apr;77(4):403-417. doi: 10.1016/j.eururo.2019.01.049. Epub 2019 Feb 14.
10
Metastatic superscan in prostate carcinoma on gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography scan.镓-68-前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描上前列腺癌的转移性超级扫描
Indian J Nucl Med. 2016 Apr-Jun;31(2):150-1. doi: 10.4103/0972-3919.178330.
Zotero 插件